Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05177770 · ClinicalTrials.gov registry record · Phase 2
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
A Phase 2 study, sponsored by Coherus Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT05177770 is a Phase 2 study that was terminated before completion, run by Coherus Oncology. The registered enrollment target is 16 participants.
The verdict
NCT05177770, a Phase 2 study, was terminated before completion, sponsored by Coherus Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).
Interventions
- DRUG etrumadenant
- DRUG SRF617
- DRUG zimberelimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-01-17 |
| Est. Completion | 2023-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05177770
The ClinicalTrials.gov registry entry for NCT05177770 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Coherus Oncology, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which etrumadenant is the first listed.
NCT05177770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05177770 about?
NCT05177770 is a clinical study titled "Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer". This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).
What is the current status of trial NCT05177770?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2022-01-17. Estimated completion is 2023-04-05.
What interventions are being tested in trial NCT05177770?
The interventions under investigation include: etrumadenant (DRUG), SRF617 (DRUG), zimberelimab (DRUG).
Who is sponsoring clinical trial NCT05177770?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.